U.S. Workforce Drug Positivity Hits 19.1% in 2025, Driven by Surging Marijuana Use
Event summary
- 19.1% of U.S. workers tested positive for drugs via hair analysis in 2025, up 46% from 2021.
- Marijuana accounted for 52.5% of hair drug positives, with pre-employment positivity rising 49.5% since 2021.
- Healthcare workers had the highest overall drug positivity rate at 5.8%, while retail trade led in marijuana use at 7.6%.
- Fentanyl positivity declined by nearly half (49.1%) year-over-year in the general workforce.
The big picture
The persistent rise in drug positivity rates, particularly for marijuana, underscores long-term substance use patterns among U.S. workers. This trend poses significant risks for workplace safety and productivity, especially in high-stakes industries like healthcare. The decline in fentanyl positivity suggests that targeted employer interventions can make an impact, but broader challenges remain as marijuana use continues to climb.
What we're watching
- Regulatory Shifts
- How the potential reclassification of marijuana from Schedule I to Schedule III will affect workplace drug testing policies.
- Industry Risks
- Whether high positivity rates in healthcare and retail sectors will drive stricter hiring or safety protocols.
- Testing Evolution
- The pace at which hair and oral fluid testing replace urine testing due to their resistance to tampering.